MOSCOW, August 4. /TASS/. Russian-Singaporean biotech company Gero, which develops new drugs using artificial intelligence, has raised $2.2 million from the international venture capital fund Bulba Ventures and other investors, the Russian company said in a statement.
"The Russian-Singaporean company Gero, which specializes in development of therapies for aging and other complex diseases using artificial intelligence, announced the closure of a new round of funding in the amount of $2.2 million. The round was headed by the international venture fund Bulba Ventures Yuri Melnichek, who joined the board directors Gero," the statement says.
The company used the raised funds to develop a platform based on artificial intelligence for analyzing clinical and genetic data and for finding drugs against the most complex diseases, such as chronic diseases associated with aging, mental illness and many others.
"We are confident that as a result, the project will reach a new level, and the company will take a confident position in the fight against critical diseases of the 21st century," founder of Gero Pyotr Fedichev said as quoted by the statement.